Antithrombotic therapy in atrial fibrillation:aspirin is rarely the right choice.

Sabir, Ian N., Matthews, Gareth D.K. ORCID: https://orcid.org/0000-0001-8353-4806 and Huang, Christopher L.H. (2013) Antithrombotic therapy in atrial fibrillation:aspirin is rarely the right choice. Postgraduate Medical Journal, 89 (1052). pp. 346-351. ISSN 1469-0756

Full text not available from this repository. (Request a copy)

Abstract

Atrial fibrillation, the commonest cardiac arrhythmia, predisposes to thrombus formation and consequently increases risk of ischaemic stroke. Recent years have seen approval of a number of novel oral anticoagulants. Nevertheless, warfarin and aspirin remain the mainstays of therapy. It is widely appreciated that both these agents increase the likelihood of bleeding: there is a popular conception that this risk is greater with warfarin. In fact, well-managed warfarin therapy (INR 2-3) has little effect on bleeding risk and is twice as effective as aspirin at preventing stroke. Patients with atrial fibrillation and a further risk factor for stroke (CHA2DS2-VASc >0) should therefore either receive warfarin or a novel oral agent. The remainder who are at the very lowest risk of stroke are better not prescribed antithrombotic therapy. For stroke prevention in atrial fibrillation; aspirin is rarely the right choice.

Item Type:	Article
Uncontrolled Keywords:	medicine(all) ,/dk/atira/pure/subjectarea/asjc/2700
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	10 Nov 2022 13:30
Last Modified:	10 Nov 2022 15:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/89767
DOI:	10.1136/postgradmedj-2012-131386

Actions (login required)

View Item